Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07309419 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma(Cocktail-001) | not yet recruiting | Phase 2 / Phase 3 | 222 | Shanghai Zhongshan HospitalOTHER | 0 | Dec 30, 2025 | clinicaltrials |
| NCT07296445 | A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)(LATITUDE) | not yet recruiting | Phase 3 | 120 | SDK Therapeutics, Inc. |
| 0 |
| Dec 29, 2025 |
| clinicaltrials |
| NCT07303231 | The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy | not yet recruiting | Phase 3 | 144 | Fujian Medical University Union HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT07297914 | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL(FORUM2) | not yet recruiting | Phase 2 / Phase 3 | 1,000 | Bambino Gesù Hospital and Research InstituteOTHER | 9 | Dec 22, 2025 | clinicaltrials |
| NCT07291102 | Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma | not yet recruiting | Phase 3 | 96 | Nationwide Children's HospitalOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT07287592 | Glutamine for the Prophylaxis of Vincristine-induced Neuropathy in Children and Adolescents With Cancer. | not yet recruiting | Phase 3 | 70 | Ain Shams UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07272109 | Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes(PTCA199-16) | not yet recruiting | Phase 3 | 210 | Fudan UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT05077215 | Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer | not yet recruiting | Phase 3 | 450 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT07268690 | Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07269691 | RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer | not yet recruiting | Phase 3 | 194 | Pengfei QiuOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07264010 | Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study | not yet recruiting | Phase 2 / Phase 3 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Dec 4, 2025 | clinicaltrials |
| NCT06787118 | Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer(PANDORA) | not yet recruiting | Phase 3 | 130 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | not yet recruiting | Phase 2 / Phase 3 | 737 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07246330 | Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study | not yet recruiting | Phase 3 | 340 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07242274 | Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC | not yet recruiting | Phase 3 | 472 | JemincareINDUSTRY | 1 | Nov 21, 2025 | clinicaltrials |
| NCT07238569 | Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 516 | Sun Yat-sen UniversityOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT07230626 | SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | not yet recruiting | Phase 3 | 412 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Nov 17, 2025 | clinicaltrials |
| NCT07213206 | CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer(Cinderella) | not yet recruiting | Phase 3 | 1,500 | Fudan UniversityOTHER | 0 | Oct 8, 2025 | clinicaltrials |
| NCT07211009 | Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial | not yet recruiting | Phase 3 | 240 | Sichuan UniversityOTHER | 0 | Oct 7, 2025 | clinicaltrials |
| NCT07197853 | Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Granules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A Prospective, Single-Center, Randomized Controlled Clinical Trial(HAMSTER) | not yet recruiting | Phase 3 | 180 | Xin YeOTHER | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | not yet recruiting | Phase 3 | 228 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07154368 | JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs. | not yet recruiting | Phase 3 | 207 | Guangzhou JOYO Pharma Co., LtdINDUSTRY | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07156786 | N-Acetylcysteine Roles in Preserving Renal Function Measured by Urinary KIM-1 (Kidney Injury Molecule-1) and Serum Creatinine on Cancer Patients With Cisplatin Based Chemotherapy: A Randomized Placebo-Controlled Trial | not yet recruiting | Phase 2 / Phase 3 | 72 | Fakultas Kedokteran Universitas IndonesiaOTHER | 0 | Sep 19, 2025 | clinicaltrials |
| NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | not yet recruiting | Phase 3 | 280 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07177716 | Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical Cancer | not yet recruiting | Phase 2 / Phase 3 | 120 | L & L Bio Co., Ltd., Ningbo, ChinaINDUSTRY | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07178457 | Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance(BeCALM) | not yet recruiting | Phase 3 | 84 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07169903 | Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT(STAR012) | not yet recruiting | Phase 3 | 587 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Sep 12, 2025 | clinicaltrials |
| NCT07157514 | Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML | not yet recruiting | Phase 2 / Phase 3 | 306 | Actinium PharmaceuticalsINDUSTRY | 0 | Sep 10, 2025 | clinicaltrials |
| NCT07165418 | A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI | not yet recruiting | Phase 3 | 116 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07162883 | Pharmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of Non-Small Cell Lung Cancer (NSCLC) | not yet recruiting | Phase 3 | 122 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 9, 2025 | clinicaltrials |
| NCT06680258 | A Study of TPST-1120 With Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic HCC Not Previously Treated With Systemic Therapy | not yet recruiting | Phase 3 | 740 | Tempest TherapeuticsINDUSTRY | 0 | Sep 3, 2025 | clinicaltrials |
| NCT07134205 | The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer | not yet recruiting | Phase 3 | 252 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Aug 21, 2025 | clinicaltrials |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Changhai HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT07124195 | Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting | not yet recruiting | Phase 3 | 126 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT07106528 | Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 2 / Phase 3 | 128 | Peking Union Medical College HospitalOTHER | 0 | Aug 6, 2025 | clinicaltrials |
| NCT06839092 | Prophylactic PIPAC in Patients With High-risk Colorectal Cancer(PROPAC) | not yet recruiting | Phase 3 | 160 | Jeremy MeyerOTHER | 0 | Jul 30, 2025 | clinicaltrials |
| NCT07074353 | Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer(CinClare-2) | not yet recruiting | Phase 3 | 360 | Zhejiang Cancer HospitalOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07082452 | A Multicenter Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction(SEVENAZA) | not yet recruiting | Phase 3 | 262 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT06580223 | Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | not yet recruiting | Phase 3 | 530 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07072000 | Shrinking the Anterior Border of CTV2 for Nasopharyngeal Carcinoma to Reduce the Radiation of Nasal Cavity | not yet recruiting | Phase 3 | 550 | Hai-Qiang Mai,MD,PhDOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT06835400 | Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer | not yet recruiting | Phase 3 | 340 | Health Hope PharmaINDUSTRY | 0 | Jul 11, 2025 | clinicaltrials |
| NCT07035821 | Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy | not yet recruiting | Phase 3 | 100 | Shanghai Children's Medical CenterOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06434077 | Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer | not yet recruiting | Phase 3 | 60 | S.LAB (SOLOWAYS)OTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT07025239 | QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer | not yet recruiting | Phase 3 | 430 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Jun 17, 2025 | clinicaltrials |
| NCT07021261 | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients | not yet recruiting | Phase 3 | 440 | Fudan UniversityOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT07005557 | Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer(SENIOR) | not yet recruiting | Phase 3 | 1,244 | Fudan UniversityOTHER | 0 | Jun 5, 2025 | clinicaltrials |
| NCT06999512 | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer(HPB70+) | not yet recruiting | Phase 2 / Phase 3 | 526 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06996093 | Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor | not yet recruiting | Phase 3 | 2,508 | Fudan UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06990503 | SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer | not yet recruiting | Phase 3 | 300 | Tongji HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06970782 | Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure(KYLIN-3) | not yet recruiting | Phase 3 | 278 | Avistone Biotechnology Co., Ltd.INDUSTRY | 0 | May 21, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 30, 2025source: clinicaltrials